<meta http-equiv="content-type" content="text/html; charset=ISO-8859-1" /><br>Title: Clinical Trials and New Drug Development: Optimal Investment Policies and Application</br><br>Author: Joseph Milner, University of Toronto, 105 St. George Street, Toronto, ON, M5S3E6, Canada, milner@rotman.utoronto.ca</br><br>Coauthor(s): Panos Kouvelis, Zhili Tian</br><br>Year: 2013</br><br>Abstract: Pharmaceutical firms enroll hundreds of patients in Phase III clinical studies at considerable cost in order to prove the safety, efficacy, and tolerability of new drugs. Delays in this process can significantly reduce the lifetime profitability of a drug. We model the enrolment process to establish optimal policies. We consider cases with and without interim analyses. We establish structural results and provide numerical results based on data.</br>